Galectin‐3 as a biomarker in breast neoplasms: Mechanisms and applications in patient care

Galectin‐3 is a member of the lectin family encoded by the LGALS3 gene on chromosome 14. It is secreted by a wide range of immune cells and mammary tumor cells. Through its activity on the tumor microenvironment, in particular on tumor‐infiltrating leukocytes, galectin‐3 improves the proliferation,...

Full description

Saved in:
Bibliographic Details
Published inJournal of leukocyte biology Vol. 112; no. 5; pp. 1041 - 1052
Main Authors Niang, Doudou Georges Massar, Gaba, Folly Mawulolo, Diouf, Adame, Hendricks, Jacobus, Diallo, Rokhaya Ndiaye, Niang, Maguette Deme Sylla, Mbengue, Babacar, Dieye, Alioune
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 01.11.2022
Subjects
Biomarkers
Breast Neoplasms - diagnosis
Breast Neoplasms - pathology
Cell proliferation
Chromosome 14
Female
Galectin 3 - genetics
Galectin-3
Humans
Immune system
Immunotherapy
Leukocytes
LGALS3 gene
M2 macrophage
Mammary gland
Neoplasms
NK cell
Therapeutic targets
TILs
Tumor cells
Tumor Microenvironment
Tumors
M2 macrophage
TILs
tumor microenvironment
NK cell
immunotherapy
Online AccessGet full text
ISSN0741-5400
1938-3673
1938-3673
DOI10.1002/JLB.5MR0822-673R

Cover

More Information
Summary:Galectin‐3 is a member of the lectin family encoded by the LGALS3 gene on chromosome 14. It is secreted by a wide range of immune cells and mammary tumor cells. Through its activity on the tumor microenvironment, in particular on tumor‐infiltrating leukocytes, galectin‐3 improves the proliferation, survival, and colonizing ability of mammary neoplastic cells. Consequently, galectin‐3 expression in the tumor microenvironment could worsen therapeutic outcomes of breast neoplasms and become a biomarker and a therapeutic target in combined immunotherapy in breast neoplasms. There is a limited amount of information that is available on galectin‐3 in breast cancer in Africa. In this review, we analyze how galectin‐3 influences the tumor microenvironment and its potential as a biomarker and therapeutic target in breast neoplasms. We aim to emphasize the significance of investigating galectin‐3 in breast neoplasms in Africa based on the results of studies conducted elsewhere. Graphical Review of the mechanisms involved in galectin‐3 breast neoplasms promotion through the tumor microenvironment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0741-5400
1938-3673
1938-3673
DOI:10.1002/JLB.5MR0822-673R